The anti-inflammatory cytokine IL-37 improves the NK cell-mediated anti-tumor response

IF 7.2 2区医学

Oncoimmunology Pub Date : 2023-12-26 DOI:10.1080/2162402x.2023.2297504

Nadine Landolina, Francesca Romana Mariotti, Andrea Pelosi, Valentina D’Oria, Tiziano Ingegnere, Claudia Alicata, Paola Vacca, Lorenzo Moretta, Enrico Maggi

引用次数: 0

Abstract

IL-37 is a member of the IL-1 superfamily exerting anti-inflammatory functions in a number of diseases. Extracellular IL-37 triggers the inhibitory receptor IL-1R8 that is known to regulate differe...

查看原文本刊更多论文

抗炎细胞因子 IL-37 可改善 NK 细胞介导的抗肿瘤反应

IL-37 是 IL-1 超家族的成员，在多种疾病中发挥抗炎功能。细胞外 IL-37 触发抑制性受体 IL-1R8，该受体可调节不同的炎症反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.